• Molecular NameBepotastine
  • Synonymbepotastine; Bepotastine besilate; Betotastine besilate; TAU-284DS
  • Weight388.895
  • Drugbank_IDDB04890
  • ACS_NO5638-76-6
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)3.2
  • pkaN/A
  • LogD (pH=7, predicted)0.69
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.96
  • LogSw (predicted, AB/LogsW2.0)0.2
  • Sw (mg/ml) (predicted, ACD/Labs)0.43
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds8
  • TPSA62.66
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug for the the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 200
  • Absorption_valueN/A
  • Absorption (description)Betahistine is readily absorbed after oral administration
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • Metabollsmpeak plasma concentrations of the metabolites are attained in 3 to 5 h.
  • Half lifeN/A
  • ExcretionMost of a dose is excreted in the urine as metabolites.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A